Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Bluebird bio, Inc.    BLUE

BLUEBIRD BIO, INC.

(BLUE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/01/2021 03/02/2021 03/03/2021 03/04/2021 03/05/2021 Date
30.08(c) 30.8(c) 29.34(c) 27.94(c) 28.68(c) Last
3 052 003 2 985 962 1 621 746 1 799 979 1 703 112 Volume
-3.28% +2.39% -4.74% -4.77% +2.65% Change
More quotes
Financials (USD)
Sales 2021 102 M - -
Net income 2021 -800 M - -
Net cash position 2021 668 M - -
P/E ratio 2021 -2,45x
Yield 2021 -
Sales 2022 233 M - -
Net income 2022 -724 M - -
Net cash position 2022 517 M - -
P/E ratio 2022 -2,92x
Yield 2022 -
Capitalization 1 926 M 1 926 M -
EV / Sales 2021 12,4x
EV / Sales 2022 6,05x
Nbr of Employees 1 201
Free-Float 98,4%
More Financials
Company
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat... 
More about the company
Notations Surperformance© of bluebird bio, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about BLUEBIRD BIO, INC.
03/04INVESTOR ACTION NOTICE : The Schall Law Firm Announces the Filing of a Class Act..
PR
03/03SHAREHOLDER ALERT : Pomerantz Law Firm Reminds Shareholders with Losses on their..
PR
03/02BLUEBIRD BIO  : Morgan Stanley Adjusts bluebird bio PT to $45 From $50, Maintain..
MT
03/01BLUEBIRD BIO  : ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages bluebird b..
PR
02/27BREAKING NOTICE : Rosen, a Globally Recognized Law Firm, Encourages bluebird bio..
BU
02/26BLUEBIRD BIO  : to Present at Cowen Health Care Conference
BU
02/24BRISTOL MYERS SQUIBB  : Bluebird Bio Phase 2 Study of Multiple Myeloma Treatment..
MT
02/24BLUEBIRD BIO  : The New England Journal of Medicine Publishes Results from Pivot..
BU
02/24GLANCY PRONGAY & MURRAY LLP  : Reminds Investors of Looming Deadline in the Clas..
BU
02/24BLUEBIRD BIO  : Barclays Adjusts bluebird bio PT to $27 From $31, Maintains Equa..
MT
02/24BLUE SHAREHOLDER ALERT : Bronstein, Gewirtz & Grossman, LLC Reminds bluebird bio..
BU
02/23BLUEBIRD : 4Q Earnings Snapshot
AQ
02/23BLUEBIRD BIO  : Management's Discussion and Analysis of Financial Condition and ..
AQ
02/23BLUEBIRD BIO, INC.  : Results of Operations and Financial Condition, Financial S..
AQ
02/23BLUEBIRD BIO  : Earnings Flash (BLUE) BLUEBIRD BIO Reports Q4 Revenue $10.7M, vs..
MT
More news
News in other languages on BLUEBIRD BIO, INC.
2020BLUEBIRD BIO, INC.  : Veröffentlichung des Jahresergebnisses
2020BLUEBIRD BIO, INC.  : publication des résultats annuels
2018ORIGINAL-RESEARCH : Medigene AG (von EQUITS GmbH): Kaufen
2018ORIGINAL-RESEARCH : Medigene AG (von EQUITS GmbH): Kaufen
2018BLUEBIRD BIO  : gibt im New England Journal of Medicine veröffentlichte Zwischen..
More news
Analyst Recommendations on BLUEBIRD BIO, INC.
More recommendations
Chart BLUEBIRD BIO, INC.
Duration : Period :
bluebird bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BLUEBIRD BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 44,28 $
Last Close Price 28,68 $
Spread / Highest target 200%
Spread / Average Target 54,4%
Spread / Lowest Target -9,34%
EPS Revisions
Managers and Directors
NameTitle
Nick Leschly President, Chief Executive Officer & Director
William Denise Baird Chief Financial & Accounting Officer
Daniel S. Lynch Chairman
David M. Davidson Chief Medical Officer
Philip D. Gregory Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
BLUEBIRD BIO, INC.-33.72%1 926
GILEAD SCIENCES, INC.10.92%81 201
VERTEX PHARMACEUTICALS-10.31%55 106
WUXI APPTEC CO., LTD.0.64%50 791
REGENERON PHARMACEUTICALS-4.46%48 070
BEIGENE, LTD.16.60%27 598